LifeVantage Corporation (Nasdaq: LFVN), a leading health and wellness company with products designed to activate optimal health processes at the cellular level, today reported financial results for its second fiscal quarter ended December 31, 2023.
Second Quarter Fiscal 2024 Summary*:
Revenue of $51.6 million, a decrease of 3.8% from the prior year period. Excluding the negative impact of foreign currency fluctuations, second quarter revenue was down approximately 3.4%;
Revenue in the Americas decreased 1.6%, and revenue in Asia/Pacific & Europe decreased 10.0%. Excluding the negative impact of foreign currency fluctuations, second quarter revenue in Asia/Pacific & Europe decreased approximately 8.0%;
Net loss per diluted share was $0.05, versus net loss of $0.08 per diluted share a year ago;
Adjusted earnings per diluted share was $0.10, compared to adjusted loss per share of $0.07 a year ago; and
Adjusted EBITDA increased 289.0% to $3.1 million.
* All comparisons are on a year over year basis and compare the second quarter of fiscal 2024 to the second quarter of fiscal 2023, unless otherwise noted.
“We delivered significant year-over-year improvement in profitability during the second quarter as our LV360 initiatives continued to gain traction,”
said Steve Fife, President and Chief Executive Officer of Life Vantage.
“Adjusted EBITDA increased 289% to $3.1 million